MedPath

Comprehensive DNA Methylation Profiling in Crohn's Disease

Conditions
Crohn Disease
Methylation
Illumina Human Methylation 850k BeadChip
Interventions
Genetic: Genome-wide DNA methylation
Registration Number
NCT03272152
Lead Sponsor
Jinling Hospital, China
Brief Summary

Previous studies have indicated that abnormal DNA methylation frequently occurs in the mucosa in Crohn's disease. Comprehensive DNA methylation profiling of the inflamed and non-inflamed ileal mucosa of patients with Crohn's disease was performed. Genome-wide DNA methylation was determined using the Illumina HumanMethylation 850k BeadChip.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
14
Inclusion Criteria
  • Active Crohn's disease(CDAI score≥ 150)
Exclusion Criteria
  • No ileal lesions
  • Under treatment of immunomodulators, biologic agents or steroids

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Inflamed CD groupGenome-wide DNA methylationInflamed ileal mucosa was obtained from inflammed lesions of active CD patients
Non-inflamed CD groupGenome-wide DNA methylationNon-inflamed ileal mucosa was obtained from normal sites of active CD patients
Control groupGenome-wide DNA methylationControl ileal mucosa was obtained from healthy patients
Primary Outcome Measures
NameTimeMethod
Intestinal inflammation under colonoscopyJan 2017 to Sep 2017

Intestinal ulcer or enteritisis observed under colonoscopy

Secondary Outcome Measures
NameTimeMethod
CDAIJan 2017 to Sep 2017

Crohns Disease Activity Index is measured.

Trial Locations

Locations (1)

Jinling Hospital

🇨🇳

Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath